TD Cowen analyst Brendan Smith has reiterated their bullish stance on MXCT stock, giving a Buy rating today.
Brendan Smith has given his Buy rating due to a combination of factors including MaxCyte’s strong execution in the first quarter and the reaffirmation of their FY25 guidance, which is considered achievable even without improvements in the market. The company has effectively managed potential risks, such as tariff impacts and NIH funding exposure, ensuring no negative effect on gross margins and minimal risk to U.S. revenues.
Furthermore, MaxCyte’s long-term outlook remains positive despite changes in FDA leadership, as they have taken proactive measures with global distributors to mitigate revenue uncertainties outside the U.S. The company’s financial health is supported by a substantial cash reserve and a manageable burn rate, providing a multi-year runway to reach adjusted EBITDA positivity. Additionally, strategic reallocations from recent cost-saving measures are expected to enhance initiatives in cell engineering and manufacturing, further solidifying their market position.
MXCT’s price has also changed moderately for the past six months – from p279.000 to p203.000, which is a -27.24% drop .